Skip to main content
  • 1040 Accesses

Abstract

Ascites is the pathological accumulation of fluid in the abdominal cavity caused by an imbalance of fluid in and out of the blood and lymphatic vessels. Portal hypertension is the major cause of ascites, but infectious and malignant causes are also very important. Cancer-induced ascites is present in about 10% of all patients. Palliation of ascites is important for holistic patient management. Median survival after diagnosis of malignant ascites was only 20 weeks from the time of diagnosis of ascites, except for tumors of ovarian and lymphatic origin, which have better mean survivals (32 and 58 weeks, respectively). The most common cancers associated with ascites are adenocarcinomas of the ovary, breast, colon, stomach, and pancreas. The cancer type largely influences the sites of abdominal metastases and the cause of the ascites. The manifestation of symptoms depends on the amount of fluid, rapidity of fluid accumulation, and the cause of ascites. Patients often first seek medical attention because of abdominal discomfort, pain, breathing difficulty, or early satiety. They may also complain of reduced appetite, nausea, vomiting, lower extremity edema, weight gain, and reduced mobility. The diagnosis is based upon the clinical setting, imaging tests, and ascitic fluid analysis. Radiologic studies are useful in detecting small amounts of ascitic fluid as well as helpful in assessing the etiology of ascites. Ultrasonography is the commonest and most convenient investigation for diagnosing ascites. Depending on the clinical setting, computed tomography or magnetic resonance imaging scans are excellent investigations. The detection of tumor cells by cytology remains the gold standard for the detection of malignancy. In most instances, the treatment of metastatic cancer with ascites is palliative. Treatment options include large-volume paracentesis, peritoneovenous shunting, drainage catheters, surgery, intraperitoneal therapy, and tumor-targeted treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology. 2004;39(3):841–56.

    Article  PubMed  Google Scholar 

  2. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42(5):589–97.

    Article  PubMed  Google Scholar 

  3. Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198(6):999–1011.

    Article  PubMed  Google Scholar 

  4. Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330(5):337–42.

    Article  CAS  PubMed  Google Scholar 

  5. Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol. 1996;6(2):474–80.

    CAS  PubMed  Google Scholar 

  6. Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites. Clinical and experimental. Ann Surg. 1986;203(6):644–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. McIntyre N, Burroughs AK. Cirrhosis, portal hypertension, and ascites. In: Weatherall DJ, Ledingham J, Warrell DA, editors. Oxford textbook of medicine. 3rd ed. Oxford: Oxford University Press; 1996. p. 2085–100.

    Google Scholar 

  8. Lifshitz S. Ascites, pathophysiology and control measures. Int J Radiat Oncol Biol Phys. 1982;8(8):1423–6.

    Article  CAS  PubMed  Google Scholar 

  9. Saif MW, Siddiqui IA, Sohail MA. Management of ascites due to gastrointestinal malignancy. Ann Saudi Med. 2009;29(5):369–77.

    Article  PubMed  PubMed Central  Google Scholar 

  10. El-Shami K, Elsaid A, El-Kerm Y. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol. 2007;25(18S):9043.

    Google Scholar 

  11. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087–107.

    Article  PubMed  Google Scholar 

  12. Cattau EL Jr, Benjamin SB, Knuff TE, Castell DO. The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA. 1982;247(8):1164–6.

    Article  PubMed  Google Scholar 

  13. Chongtham DS, Singh MM, Kalantri SP, Pathak S. A simple bedside manoeuvre to detect ascites. Natl Med J India. 1997;10(1):13–4.

    CAS  PubMed  Google Scholar 

  14. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117(3):215–20.

    Article  CAS  PubMed  Google Scholar 

  15. Akriviadis EA. Hemoperitoneum in patients with ascites. Am J Gastroenterol. 1997;92(4):567–75.

    CAS  PubMed  Google Scholar 

  16. Kielhorn E, Schofield K, Rimm DL. Use of magnetic enrichment for detection of carcinoma cells in fluid specimens. Cancer. 2002;94(1):205–11.

    Article  PubMed  Google Scholar 

  17. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945–9.

    Article  CAS  PubMed  Google Scholar 

  18. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology. 1998;27(1):264–72.

    Article  CAS  PubMed  Google Scholar 

  19. Sharma S, Walsh D. Management of symptomatic malignant ascites with diuretics: two case reports and a review of the literature. J Pain Symptom Manage. 1995;10(3):237–42.

    Article  CAS  PubMed  Google Scholar 

  20. Greenway B, Johnson PJ, Williams R. Control of malignant ascites with spironolactone. Br J Surg. 1982;69(8):441–2.

    Article  CAS  PubMed  Google Scholar 

  21. Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manage. 1998;16(2):96–101.

    Article  CAS  PubMed  Google Scholar 

  22. Rosenberg SM. Palliation of malignant ascites. Gastroenterol Clin North Am. 2006;35(1):189–99. xi

    Article  PubMed  Google Scholar 

  23. Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol (R Coll Radiol). 2003;15(2):59–72.

    Article  CAS  Google Scholar 

  24. Straus AK, Roseman DL, Shapiro TM. Peritoneovenous shunting in the management of malignant ascites. Arch Surg. 1979;114(4):489–91.

    Article  CAS  PubMed  Google Scholar 

  25. Schumacher DL, Saclarides TJ, Staren ED. Peritoneovenous shunts for palliation of the patient with malignant ascites. Ann Surg Oncol. 1994;1(5):378–81.

    Article  CAS  PubMed  Google Scholar 

  26. Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol. 1996;22(3):237–9.

    Article  CAS  PubMed  Google Scholar 

  27. Belfort MA, Stevens PJ, DeHaek K, Soeters R, Krige JE. A new approach to the management of malignant ascites; a permanently implanted abdominal drain. Eur J Surg Oncol. 1990;16(1):47–53.

    CAS  PubMed  Google Scholar 

  28. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1–11.

    CAS  PubMed  Google Scholar 

  31. Tewari D, Java JJ, Salani R, Armstrong DK, Mrkman M, Herzog T, Monk BJ, Chan JK. Long term survival advantage and prognostic factors associated with intraperitoneal chemotherapy in advanced ovarian cancer: a gynaecologic oncology group study. J Clin Oncol. 2015;33(13):1460–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Bellati F, Napoletano C, Ruscito I, et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs. 2010;28(6):887–94. https://doi.org/10.1007/s10637-009-9351-4.

    Article  CAS  PubMed  Google Scholar 

  33. Gotlieb W, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF, Vergote I. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascities in patients with advanced ovarian cancer: a phase 2, randomized, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154.

    Article  CAS  PubMed  Google Scholar 

  34. Aleem A, Siddiqui N. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate. Leuk Lymphoma. 2005;46(7):1097–9.

    Article  CAS  PubMed  Google Scholar 

  35. Ng T, Pagliuca A, Mufti GJ. Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin’s lymphoma. Ann Hematol. 2002;81(7):405–6.

    Article  CAS  PubMed  Google Scholar 

  36. Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment options. Oncology (Williston Park). 2004;18(1):51–9.

    Google Scholar 

  37. Chua TC, Al-Alem I, Saxena A, Liauw W, Morris DL. Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluatin of 46 consecutive patients. Ann Surg Oncol. 2011;18(6):1540.

    Article  PubMed  Google Scholar 

  38. Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative findings, early complications and long term survival in 456 patients wih pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54(3):293.

    Article  PubMed  Google Scholar 

  39. Parsons S, Hennig M, Linke R, Klein A, Lahr A, Lindhofer H, Heiss M. The trifunctional antibody catumaxomab for the treatment of malignant ascities due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Strohlein MA, Heiss MM. The trifunctional antibody catumaxomab in treatment of malignant ascities and peritoneal carcinomatosis. Future Oncol. 2010;6(9):1387–94.

    Article  PubMed  Google Scholar 

  41. Woopen H, Sehouli J. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res. 2009;29(8):3353–9.

    PubMed  Google Scholar 

  42. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS. Catumaxomab for the treatment of malignant ascities in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynaecol Cancer. 2014;24(9):1583.

    Article  Google Scholar 

  43. Chester C, Dorigo O, Berek J, Kohrt H. Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer. 2015;3:7.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Sangisetty SL, Miner TJ. Malignant ascities: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrintest Surg. 2012;4(4):87–95.

    Article  Google Scholar 

Download references

Acknowledgments

Dr. Joseph Thomas, MD: Professor and Head of Medical Oncology, Shirdi Sai Baba Cancer Hospital and Research Centre, Kasturba Medical College, Manipal. Karnataka 576104; Mr. Ashok VK, Product Manager, Dr. Reddy’s Laboratories, Hyderabad, Andhra Pradesh.; Dr H Hong, Medical Oncology, Lyell McEwin Hospital, Elizabeth Vale SA 5112

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rohit Joshi .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Joshi, R., Hong, H.W. (2018). Ascites. In: Olver, I. (eds) The MASCC Textbook of Cancer Supportive Care and Survivorship. Springer, Cham. https://doi.org/10.1007/978-3-319-90990-5_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90990-5_29

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90989-9

  • Online ISBN: 978-3-319-90990-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics